期刊文献+

Benfotiamine prevents increased β-amyloid production in HEK cells induced by high glucose

Benfotiamine prevents increased β-amyloid production in HEK cells induced by high glucose
原文传递
导出
摘要 Objective To determine whether high glucose enhances β-amyloid (Aβ) production in HEK293 Swedish mutant (APPsw) cells with Aβ precursor protein (APP) overexpression, and whether under this condition benfotiamine reduces the increased Aβ production. Methods HEK293 APPsw cells were cultured with different concentrations of glucose for different times. TheAβ content in the supernatant was determined by ELISA. To investigate the mechanism by which benfotiamine reduced Aβ production, glycogen synthase kinase-3 (GSK-3) activity and expression were measured after the cells were cultured with 5.5 g/L glucose for 12 h. Results With 1.0, 3.0, 4.5, 5.5, 6.5, 7.5, 8.5, or 10.5 g/L glucose, Aβ production by HEK293 APPsw cells was highest in the presence of 5.5 g/L glucose for 6 and 12 h. The difference in Aβ content between 5.5 and 1.0 g/L was most marked after incubation for 12 h. Benfotiamine at 20 and 40 μg/mL significantly reduced Aβ production in cells incubated with 5.5 g/L glucose for 12 h. Moreover, 40 μg/mL benfotiamine significantly enhanced the ratio of phosphorylated GSK-3 to total GSK-3, together with consistent down-regulation of GSK-3 activity. Conclusion High glucose increases Aβ production by HEK293 APPsw cells while benfotiamine prevents this increase. This is correlated with the modulation of GSK-3 activity. Objective To determine whether high glucose enhances β-amyloid (Aβ) production in HEK293 Swedish mutant (APPsw) cells with Aβ precursor protein (APP) overexpression, and whether under this condition benfotiamine reduces the increased Aβ production. Methods HEK293 APPsw cells were cultured with different concentrations of glucose for different times. TheAβ content in the supernatant was determined by ELISA. To investigate the mechanism by which benfotiamine reduced Aβ production, glycogen synthase kinase-3 (GSK-3) activity and expression were measured after the cells were cultured with 5.5 g/L glucose for 12 h. Results With 1.0, 3.0, 4.5, 5.5, 6.5, 7.5, 8.5, or 10.5 g/L glucose, Aβ production by HEK293 APPsw cells was highest in the presence of 5.5 g/L glucose for 6 and 12 h. The difference in Aβ content between 5.5 and 1.0 g/L was most marked after incubation for 12 h. Benfotiamine at 20 and 40 μg/mL significantly reduced Aβ production in cells incubated with 5.5 g/L glucose for 12 h. Moreover, 40 μg/mL benfotiamine significantly enhanced the ratio of phosphorylated GSK-3 to total GSK-3, together with consistent down-regulation of GSK-3 activity. Conclusion High glucose increases Aβ production by HEK293 APPsw cells while benfotiamine prevents this increase. This is correlated with the modulation of GSK-3 activity.
出处 《Neuroscience Bulletin》 SCIE CAS CSCD 2012年第5期561-566,共6页 神经科学通报(英文版)
基金 supported by grants from the National Natural Science Foundation of China(81071019) the International Cooperation Foundation of Shanghai Municipality, China (10430709600) the Outstanding Academic Leaders Foundation in Shanghai, China(11XD1401500)
关键词 Alzheimer’s disease Β-AMYLOID high glucose BENFOTIAMINE glycogen synthase kinase Alzheimer’s disease; β-amyloid; high glucose; benfotiamine; glycogen synthase kinase
  • 相关文献

参考文献30

  • 1Jolivalt CG, Lee CA, Beiswenger KK, Smith JL, Orlov M, Torrance MA, et al. Defective insulin signaling pathway and increased glycogen synthase kinase-3 activity in the brain of diabetic mice: parallels with Alzheimer's disease and correction by insulin. J Neurosci Res 2008, 86(15): 3265-3274.
  • 2Pasquier F, Boulogne A, Leys D, Fontaine P. Diabetes mellitus and dementia. Diabetes Metab 2006, 32(5 Pt 1): 403-414.
  • 3Arvanitakis Z, Wilson RS, Bienias JL, Evans DA, Bennett DA. Diabetes mellitus and risk of Alzheimer disease and decline in cog- nitive function. Arch Neurol 2004, 61(5): 661466.
  • 4Peila R, Rodriguez BL, Lanner LJ. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu- Asia Aging Study. Diabetes 2002, 51(4): 1256-1262.
  • 5Bosco D, Fava A, Plastino M, Montalcini T, Pujia A. Possible im- plications of insulin resistance and glucose metabolism in Alzheim- er's disease pathogenesis. J Cell Mol Med 2011, 15(9): 1807-1821.
  • 6Biessels GJ, Kappelle LJ. Increased risk of Alzheimer's disease in Type Ⅱ diabetes: insulin resistance of the brain or insulin-induced amyloid pathology. Biochem Soc Trans 2005, 33(Pt 5): 1041-1044.
  • 7Liu Y, Liu F, Grundke-Iqbal I, Iqbal K, Gong CX. Brain glucose transporters, O-GlcNAcylation and phosphorylation of tau in diabe- tes and Alzheimer's disease. J Neurochem 2009, 111 (1): 242-249.
  • 8Mosconi L, Pupi A, De Leon MJ. Brain glucose hypometabolism and oxidative stress in preclinical Alzheimer's disease. Ann N Y Acad Sci 2008, 1147: 180-195.
  • 9Li L, Holscher C. Common pathological processes in Alzheimer disease and type 2 diabetes: a review. Brain Res Rev 2007, 56(2): 384--402.
  • 10Takashima A. GSK-3 is essential in the pathogenesis of Alzheim- er's disease. J Alzheimers Dis 2006, 9(3 Suppl): 309-317.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部